EU regulators begin review of LEO's IL-13 monoanti-tralokinumab to treat adhetular dermatitis

The Eu drug regulator has begun a review of LEO Pharma's leukocyte interleukin 13 (IL-13) monoanti-tralokinumab treatment for moderate to severe adhesional dermatitisThe drug is an all-human monoclonal antibody that neutralises IL-13 cytokine, a potential key driver of ad hoc dermatitisThe application is based on data from key ECZTRA 1, 2 and 3 Phase III studies that assessed the efficacy and safety of traokinumabIn the trial, after 16 weeks of treatment, patients showed clear or almost transparent skin, and at week 16 the eczema area and severity index (EASI) score changed at least 75% or more from the baselineIn addition, the overall rate of adverse events was comparable to that of placebos"People with epitoma dermatitis often face enormous physical, social, and emotional challenges," said Kim Kj?ller, executive vice president of global research and development at LEO Pharma"Since atopic dermatitis is a heterogeneous disease, we focus on targeted treatments to meet individual needs and reduce the burden of disease"